CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, and Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical collaboration to conduct a Phase 1 trial in China, planned to begin in 2026. The trial will […]

Veteran advisor focused on empathetic service, transparent guidance, and lifelong client relationships selects Cetera to support her growth plans Cetera welcomes financial advisor Kim Ramchandani and her deeply personal, relationship-driven approach to financial planning that emphasizes education, transparency and long-term client support. She now is affiliating with Cetera after nearly 20 years at LPL, where

(NASDAQ:SLDB), CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the first participant has been dosed in FALCON, the Company's Phase 1b, first-in-human clinical trial evaluating SGT-212, its investigational gene therapy

(NASDAQ:CARL), Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024 CARLSBAD, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced preliminary and

(NASDAQ:BLLN), MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reiterated the full year 2025 guidance of $293 million to $299 million with positive GAAP operating income and initiated the full

(NASDAQ:MXCT),(LSE:MXCT),(LSE:MXCN), ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2025. Preliminary

Financing led by institutional investors, with participation from new investor Eli Lilly and Company Inclusive of this investment, a total of $123 million in equity financing received from institutional and strategic investors to date Separately, Recludix announces collaboration with Lilly to utilize Lilly TuneLab(TM), a pioneering artificial intelligence and machine learning platform, to accelerate the

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollment GlobeNewswire January 12, 2026 CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB)

Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025 GlobeNewswire January 12, 2026 Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024 CARLSBAD, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the

BillionToOne Provides Guidance for 2026 GlobeNewswire January 12, 2026 MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reiterated the full year 2025 guidance of $293 million to $299 million with